阿德福韦酯长期治疗对慢性乙型肝炎患者PBMCs中线粒体DNA的影响*

doi:10.3969/j.issn.1672-5069.2012.01.004

实用肝脏病杂志 ›› 2012, Vol. 15 ›› Issue (1): 10-13.doi: 10.3969/j.issn.1672-5069.2012.01.004

阿德福韦酯长期治疗对慢性乙型肝炎患者PBMCs中线粒体DNA的影响*

刘晓宇, 周莉, 段钟平, 赵彩彦

050051 石家庄市河北医科大学附属第三医院感染病科（刘晓宇,赵彩彦）; 首都医科大学附属北京佑安医院人工肝中心（周莉,段钟平）

收稿日期:2011-09-09 出版日期:2012-02-10 发布日期:2016-05-11
通讯作者: 赵彩彦,E-mail：zhaocy2005@163.com
作者简介:刘晓宇女, 26岁, 硕士研究生。E-mail：lxyu6@126.com 共同周莉女, 33岁,医学博士,副主任医师。E-mail：doctorzl@gmail.com
基金资助:
北京市丰台区科技项目（项目编号xm101210）; 中国艾滋病和结核病多学科应用培训项目（编号5U2RTW006918-08）

The changes of mitochondrial DNA levels in peripheral blood monouclear cells in patients with chronic hepatitis b receiving long-term adefovir treatment

Liu Xiaoyu, Zhou Li, Duan Zhongping, et al

Department of Infectious Disease,the Third Affiliated Hospital,Hebei Medical University,Shijiazhuang 050051,China

Received:2011-09-09 Online:2012-02-10 Published:2016-05-11
Contact: Corresponding author:ZHAO Caiyan,E-mail: zhaocy2005@163.com

摘要/Abstract

摘要： 目的探讨长期服用阿德福韦酯对CHB患者外周血单个核细胞（PBMCs）线粒体的可能损伤。方法本研究包括18例服用阿德福韦酯2年、25例服用3年和22例未服用阿德福韦酯的CHB患者;采用实时定量PCR法检测各组患者PBMCs中线粒体DNA（mtDNA）含量（mtDNA/nDMA）;采用ELISA法检测血浆丙二醛（MDA）、F2-isoprostanes含量;采用分光光度法检测血浆总抗氧化能力（TAOC）。结果2年组患者mtDNA含量为0.6±0.4copies/cell,3年组为0.8±0.5copies/cell,均显著低于对照组（1.4±1.2 copies/cell,P均<0.05）;2年组F2-isoprostanes含量为1.5±0.8ng/ml, 3年组为2.2±1.3ng/ml,显著低于对照组（3.7±2.7ng/ml,P均<0.05）;2年组TAOC含量为3.0±1.1单位/毫升,3年组为2.3±1.4单位/毫升,显著低于对照组（4.3±1.8单位/毫升,P均<0.05）。3组间MDA含量无统计学差异（F=2.404,P>0.05）。结论长期应用阿德福韦酯治疗慢性乙型肝炎,对PBMCs中mtDNA水平有一定的影响,其意义还有待探讨。

关键词: 慢性乙型肝炎, 阿德福韦酯, 外周血单个核细胞, 线粒体损伤, 氧化应激

Abstract: Objective To observe the changes of mitochondrial DNA levels in peripheral blood monouclear cells in patients with chronic hepatitis B receiving long-term adefovir treatment.Methods Patients with CHB were divided into three groups:（1） 2 years group（n=18）:receiving adefovir for 2 years;（2）3 years group（n=25）:adefovir for 3 years;and （3） control group（n=22）:naive patients without antiviral treatment.The mtDNA of PBMCs were detected by quantitative real-time PCR. Plasma MDA and F2-isoprostanes were measured by ELISA and TAOC were detected by spectrophotometry.Results The mtDNA in PBMCs in the 2-year treatment group was 0.6±0.4 copies/cell and in the 3-year treatment group was 0.8±0.5 copies/cell,both significantly lower than in the control group（1.4±1.2copies/cell,P<0.05）;the F2-isoprostanes in 2-year treatment group was 1.5±0.8 ng/ml and in 3-year treatment group was 2.2±1.3ng/ml,much lower than that in the control group（3.7±2.7 ng/ml,P<0.05）;the TAOC in 2-year treatment group was 3.0±1.1 IU/ml,and in 3-year treatment group was 2.3±1.4IU/ml, significantly lower than in the control group（4.3±1.8 IU/ml,P<0.05）.Conclusion The long-term administration of adefovir might injure mitochondrial DNA.

Key words: Hepatitis B, Adefovir, Peripheral blood monouclear cells, Mitochondria, Oxidative stress

刘晓宇, 周莉, 段钟平, 赵彩彦. 阿德福韦酯长期治疗对慢性乙型肝炎患者PBMCs中线粒体DNA的影响*[J]. 实用肝脏病杂志, 2012, 15(1): 10-13.

Liu Xiaoyu, Zhou Li, Duan Zhongping, et al. The changes of mitochondrial DNA levels in peripheral blood monouclear cells in patients with chronic hepatitis b receiving long-term adefovir treatment[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2012, 15(1): 10-13.

参考文献

[1] Fontana RJ. Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology,2009, （5 Suppl）:S185-195.
[2] Lewis W,Day BJ,Copeland WC. Mitochondrial toxicity of NRTI antiviral drugs:an integrated cellular perspective. Nat Rev Drug Discov,2003,2（10）:812-822.
[3] 王桂爽,蔡皓东. 阿德福韦酯和替诺福韦相关性肾小管病. 药物不良反应杂志,2010,12（1）:31-40.
[4] Tanji N,Tanji K,Kambhan N,et al. Adefovir nephrotoxicity: possible role of mitochondrial DNA depletion. Hum Pathol,2001,32（7）:734-740.
[5] Isnard-Bagnis C,Moulin B,Launay-Vacher V,et al. Anticancer drug-induced nephrotoxicity. Nephrol Ther,2005,1（2）:101-114.
[6] 吴焱,伦文辉, 闫会文,等. HAART相关症状性高乳酸血症的临床特征及影响因素分析. 中国艾滋病性病,2009,15（1）:4-8.
[7] Chiappini F,Teicher E,Saffroy R,et al. Relationship between polymerase gamma（POLG） polymorphisms and antiretroviral therapy-induced lipodystrophy in HIV-1 infected patients:a case-control study. Curr HIV Res,2009,7（2）:244-253.
[8] 吴荣荣,陈红鸽,刘淼,等. 替比夫定引起神经肌肉病变的临床观察. 中国新药杂志,2009,18（20）:2004-2008.
[9] Klusa V,Pupure J,Isajevs S,et al. Protection of azidothymidine-induced cardiopathology in mice by mildronate,a mitochondria-targeted drug. Basic Clin Pharmacol Toxicol,2006,99（4）:323-328.
[10] Arenas-Pinto A,Bhaskaran K,Dunnd D,et al. The risk of developing peripheral neuropathy induced by nucleoside reverse transcriptase inhibitors decreases over time: evidence from the Delta trial. Antivir Ther,2008,13（2）:289-295.
[11] 吴亚松,陈新月,石英,等. HIV 感染和抗反转录病毒治疗对PBMC线粒体DNA含量影响. 北京医学,2010,32（6）:431-436.
[12] Chene G,Amellal B,Pedrono G,et al. Changes in the peripheral blood mtDNA levels in naive patients treated by different nucleoside reverse transcriptase inhibitor combinations and their association with subsequent lipodystrophy.AIDS Res Hum Retroviruses,2007,23（1）:54-61.
[13] 中华医学会传染病与寄生虫病学分会、肝病学分会.病毒性肝炎防治方案. 中华肝脏病杂志,2000,8:324-329.
[14] 张树林,吴宁强,梁雪松,等. HBV侵犯PBMC致线粒体功能改变. 世界华人消化杂志,1997,5（12）:783-784.
[15] Tan C,Guo H,Zheng M,et al. Involvement of mitochondrial permeability transition in hepatitis B virus replication. Virus Res,2009,145（2）:307-311.
[16] 林纳,李丹,陈红英,等. HBV X基因对成人肝细胞HL-7702线粒体功能的影响. 细胞与分子免疫学杂志,2008,24（10）:972-974.
[17] Stankov MV,Lucke T,Das AM,et al. Mitochondrial DNA depletion and respiratory chain activity in primary human subcutaneous adipocytes treated with nucleoside analogue reverse transcriptase inhibitors. Antimicrob Agents Chemother,2010,54（1）:280-287.
[18] De Mendoza C,De Ronde A,Smolders K,et al. Changes in mitochondrial DNA copy number in blood cells from HIV-infected patients undergoing antiretroviral therapy. AIDS Res Hum Retroviruses,2004,20（3）:271-273.
[19] Timmermans EC,Tebas P,Ruiter JP,et al. Real-time nucleic acid sequence-based amplification assay to quantify changes in mitochondrial DNA concentrations in cell cultures and blood cells from HIV-infected patients receiving antiviral therapy. Clin Chem,2006,52（6）:979-987.
[20] Wang CN,Chen JY,Sabu S,et al. Elevated amniotic fluid F2-isoprostane:a potential predictive marker for preeclampsia. Free Radic Biol Med,2011,50（9）:1124-1130.
[21] Hermsdorff HH,Puchau B,Volp AC,et al. Dietary total antioxidant capacity is inversely related to central adiposity as well as to metabolic and oxidative stress markers in healthy young adults. Nutr Metab （Lond,2011,8（1）:59.
[22] Long J,Wang X,Gao H,et al. Malonaldehyde acts as a mitochondrial toxin: inhibitory effects on respiratory function and enzyme activities in isolated rat liver mitochondria. Life Sci,2006,79（15）:1466-1472.
[23] Basu S. Radioimmunoassay of 8-iso-prostaglandin F2alpha:an index for oxidative injury via free radical catalysed lipid peroxidation. Prostaglandins Leukot Essent Fatty Acids,1998,58（4）:319-325.
（校对：陈从新）

阿德福韦酯长期治疗对慢性乙型肝炎患者PBMCs中线粒体DNA的影响*

The changes of mitochondrial DNA levels in peripheral blood monouclear cells in patients with chronic hepatitis b receiving long-term adefovir treatment

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	朱凌云, 张茂海, 崔莎莎, 张秋萍. 慢性乙型肝炎患者血清IL-12、IL-18水平和外周血单个核细胞FOXp3基因水平研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 816-819.
[2]	石莹莹, 王元喜. 替比夫定联合阿德福韦酯治疗慢性乙型肝炎患者效果及其对肾功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 820-823.
[3]	闵峰, 黄文琪, 吴卫兵, 张丽, 范荣华. 慢性乙型肝炎患者血清脂肪细胞因子水平变化及其临床意义^*[J]. 实用肝脏病杂志, 2019, 22(6): 824-827.
[4]	张迎明, 申爽, 田飞, 孙园园. IFNL4和IL-28B基因多态性检测评估慢性乙型肝炎患者抗病毒治疗应答价值分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 828-831.
[5]	李传杰, 徐静, 王亮亮, 潘劲劲, 刘波. 恩替卡韦治疗慢性乙型肝炎患者血清HBsAg变化与病毒学应答的相关性研究[J]. 实用肝脏病杂志, 2019, 22(6): 928-929.
[6]	赵协山, 伍春瑢, 王春峰, 余积洁, 何青. 替诺福韦联合安络化纤丸治疗HBeAg阴性慢性乙型肝炎患者疗效及其血清肝纤维化指标的变化研究*[J]. 实用肝脏病杂志, 2019, 22(5): 644-647.
[7]	涂杰霞, 王安娜, 廖若汐. 干扰素α-2b与聚乙二醇干扰素α-2a治疗慢性乙型肝炎患者疗效比较研究*[J]. 实用肝脏病杂志, 2019, 22(5): 648-651.
[8]	高伟, 侯勇. 肝脏硬度值检测诊断慢性乙型肝炎患者肝组织纤维化的效能分析*[J]. 实用肝脏病杂志, 2019, 22(5): 652-655.
[9]	张胥磊, 杨庆余, 韩秋玉, 缪鋆鋆, 蔡仁诚, 马亦旻. 自拟中药治疗非酒精性脂肪性肝病患者血清炎症反应指标水平的变化*[J]. 实用肝脏病杂志, 2019, 22(5): 660-663.
[10]	白一春, 邓霁红, 梅小平. 影响聚乙二醇干扰素α-2b治疗慢性乙型肝炎患者疗效的多因素分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 490-493.
[11]	程华, 鞠辉, 宋德顺, 李伟. 慢性乙型肝炎患者血清血管生成素样蛋白2和高尔基体蛋白73水平变化及其诊断显著肝纤维化的效能分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 494-497.
[12]	李高明, 吕必华. 菖郁逍遥散治疗慢性乙型肝炎伴抑郁患者负性情绪和中医证候积分的变化^*[J]. 实用肝脏病杂志, 2019, 22(4): 498-501.
[13]	余英芳, 温生宝. 应用磁共振DWI单指数、双指数和拉伸指数模型参数评估慢性乙型肝炎患者肝纤维化程度效能研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 502-505.
[14]	闫瑞斌, 马淑梅, 卓玛, 乔志忠, 刘潇. 慢性乙型肝炎患者血清MMP-2和TIMP-2水平及超声检查指标评估肝纤维化分期意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(4): 506-509.
[15]	张亚飞, 叶珺, 谢琴秀, 邹桂舟, 李家斌, 李旭, 张振华. 不同医院无创性肝纤维化指标预测慢性乙型肝炎患者肝纤维化效能差异分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 510-513.